Program
sibeprenlimab
Also written as “Sibeprenlimab”, “Sibeprenlimab 400 mg” and “Sibeprenlimab 400 mg s.c. Q4weeks”.
Its studies are mostly in Glomerulonephritis, IGA · Autoimmune Diseases · Nephrosis, Lipoid, led by Otsuka.
Furthest: phase 3, since Feb 18, 20228 company-led studies, 6 open or runningNext primary completion: Mar 13, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 86 open or running | phase 3since Feb 18, 2022 | Oct 10, 2018 | Mar 13, 2027phase 2 · NCT06928142 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2018First study: phase 1 study in Glomerulonephritis, IGAFirst studyNCT03719443 · 51 enrolled · United States
- Feb 18, 20222 phase 3 studies in Glomerulonephritis, IGANCT05248659, NCT05248646
- Dec 13, 2024Phase 2 study in Glomerulonephritis, IGANCT06740526 · 56 enrolled · United States, Argentina, Canada and more
- Mar 25, 2025Phase 2 study in Autoimmune DiseasesNCT06928142 · 83 enrolled · United States, Argentina, Bulgaria and more
- Apr 24, 2025Phase 1 study in Healthy Subjects (HS)NCT07105124 · 24 enrolled · China
- Aug 13, 2026Phase 3 study in Glomerulonephritis, IGANCT07770815 · 24 planned
- Sep 30, 2026Phase 2 study in Nephrosis, LipoidNCT07861113 · 20 planned
Ahead
- Mar 13, 2027Primary completion: phase 2 study in Autoimmune DiseasesNCT06928142
- Jun 15, 2028Primary completion: phase 2 study in Nephrosis, LipoidNCT07861113
- Dec 28, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT06740526
- Dec 28, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT05248659
TargetBeta
TNFSF13 →read by rule
“Tumor necrosis factor ligand superfamily member 13 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zigakibart | Novartis | phase 3 | 6 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07861113Nephrosis, Lipoid | 2 | Not yet recruiting | Jun 15, 2028 | 20 |
| NCT07770815Glomerulonephritis, IGA | 3 | Not yet recruiting | Dec 29, 2029 | 24 |
| NCT07105124Healthy Subjects (HS) · China | 1 | Completed | Feb 15, 2023 | 24 |
| NCT06928142Autoimmune Diseases · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Mar 13, 2027 | 83 |
| NCT06740526Glomerulonephritis, IGA · United States, Argentina, Canada and more | 2 | Active, not recruiting | Dec 28, 2028 | 56 |
| NCT05248659Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | By invitation | Dec 28, 2028 | 600 |
| NCT05248646Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 13, 2026 | 530 |
| NCT03719443Glomerulonephritis, IGA · United States | 1 | Completed | Aug 10, 2019 | 51 |
How it is read
Names in the registry
- “Sibeprenlimab”, 5 entries
- “Sibeprenlimab 400 mg”, 1 entry
- “Sibeprenlimab 400 mg s.c. Q4weeks”, 1 entry
- “VIS649”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 5 studies
- Autoimmune Diseases, 1 study
- Nephrosis, Lipoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.